EMERGENT BIOSOLUTIONS INC. Business Acquisition, Pro Forma Net Income (Loss)
EMERGENT BIOSOLUTIONS INC. (EBS) reported Business Acquisition, Pro Forma Net Income (Loss) of $27.70 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2019-02-22
- EMERGENT BIOSOLUTIONS INC. business acquisition, pro forma net income (loss) for fiscal 2018 was $27.70M, a 125.20% increase from fiscal 2017.
- EMERGENT BIOSOLUTIONS INC. business acquisition, pro forma net income (loss) for fiscal 2017 was $12.30M.
- EMERGENT BIOSOLUTIONS INC. business acquisition, pro forma net income (loss) for fiscal 2014 was $34.62M, a 214.94% increase from fiscal 2013.
- EMERGENT BIOSOLUTIONS INC. business acquisition, pro forma net income (loss) for fiscal 2013 was $10.99M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|
| 2018-12-31 | $27.70M 10-K · filed 2019-02-22 |
| 2017-12-31 | $12.30M 10-K · filed 2019-02-22 |
| 2014-12-31 | $34.62M 10-K · filed 2016-02-29 |
| 2013-12-31 | $10.99M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |